Puma Biotechnology, Inc.
Rank #11ValuePBYI · Nasdaq · Healthcare
Puma Biotechnology, Inc. (PBYI) — Rank #11 by gross profitability (GP/assets 0.88) · ROE 22.5% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001401667 · all metrics point-in-time as of the filing date.
About
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Show moreShow less
It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc.
was founded in 2010 and is headquartered in Los Angeles, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- pumabiotechnology.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilitystable
- Net cashimproving
- Operating marginimproving
- Return on equitydeteriorating
- Share count (dilution)deteriorating
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-29 | 2022-12-31filed 2023-03-02 | 2021-12-31filed 2022-03-03 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 230.5 | 235.6 | 228.0 | 253.2 |
| Revenue growth (YoY) | -2.2% | 3.3% | -9.9% | 12.5% |
| Gross profit | 166.1 | 173.0 | 172.9 | 189.5 |
| Gross margin | 72.1% | 73.4% | 75.8% | 74.8% |
| Net income | 30.3 | 21.6 | 0.0 | (29.1) |
| Net margin | 13.1% | 9.2% | 0.0% | -11.5% |
| EPS (diluted) | $0.62 | $0.45 | $0.00 | — |
| EPS growth (YoY) | 37.8% | — | — | — |
| Cash flow | ||||
| Operating cash flow | 38.9 | 27.0 | (15.8) | 20.7 |
| Capital expenditures | 0.1 | 0.1 | 0.0 | 0.0 |
| Free cash flow | 38.9 | 26.9 | (15.8) | 20.7 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?